Literature DB >> 12883457

Serum cytokine level and production of reactive oxygen species (ROS) by blood neutrophils from a schizophrenic patient with hypersensitivity to neuroleptics.

Teresa Kamińska1, Agnieszka Szuster-Ciesielska, Alicja Wysocka, Halina Marmurowska-Michałowska, Halina Dubas-Slemp, Martyna Kandefer-Szerszeń.   

Abstract

BACKGROUND: There have been few publications concerning the role of the immune system in neuroleptic intolerance. Some studies have shown that in neuroleptic malignant syndrome (NMS), associated with disseminated intravascular coagulation (DIC), the serum level of tumor necrosis factor alpha (TNF-alpha) increases significantly, which is thought to trigger the onset of DIC. CASE REPORT: A 23-year-old woman suffering from catatonic schizophrenia developed hypersensitivity to neuroleptics. One month before being referred to the present authors, she had a haloperidol-induced NMS episode in another psychiatric hospital, with high temperature, CPK activity, muscle rigidity and leukocytosis. On admission to our clinic and after treatment with promazine, laboratory tests showed an increase in serum CPK activity and mild leukocytosis. Neuroleptic treatment was discontinued, and the serum level of CPK and white blood cell count was monitored daily for 7 days, as well as the serum level of some cytokines and the production of reactive oxygen species (ROS) by blood neutrophils. The serum levels of interleukin 1 alpha (IL-1), IL-6 and TNF-alpha changed significantly over the observation period, forming waves with peak activity of IL-6 and TNF-alpha exceeding normal levels. The level of IL-1 alpha was within the control range. ROS production by the patient's blood neutrophils was also increased, as well as catalase serum activity.
CONCLUSIONS: Some proinflammatory cytokines may participate in the mechanisms leading to the development of neuroleptic intolerance in schizophrenic patients. Cytokine-stimulated ROS production may participate in tissue injury and increase CPK serum activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12883457

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  8 in total

1.  Is the anti-psychotic, 10-(3-(dimethylamino)propyl)phenothiazine (promazine), a potential drug with which to treat SARS infections? Lack of efficacy of promazine on SARS-CoV replication in a mouse model.

Authors:  Dale L Barnard; Craig W Day; Kevin Bailey; Matthew Heiner; Robert Montgomery; Larry Lauridsen; Kie-Hoon Jung; Joseph K-K Li; Paul K S Chan; Robert W Sidwell
Journal:  Antiviral Res       Date:  2008-01-11       Impact factor: 5.970

2.  Pycnogenol attenuates the symptoms of immune dysfunction through restoring a cellular antioxidant status in low micronutrient-induced immune deficient mice.

Authors:  Jeongmin Lee; Da-Eun Nam; Ok-Kyung Kim; Myung-Yul Lee
Journal:  Nutr Res Pract       Date:  2014-06-30       Impact factor: 1.926

Review 3.  The pathophysiological basis and consequences of fever.

Authors:  Edward James Walter; Sameer Hanna-Jumma; Mike Carraretto; Lui Forni
Journal:  Crit Care       Date:  2016-07-14       Impact factor: 9.097

Review 4.  Neuroleptic malignant syndrome: an easily overlooked neurologic emergency.

Authors:  Ramadhan Oruch; Ian F Pryme; Bernt A Engelsen; Anders Lund
Journal:  Neuropsychiatr Dis Treat       Date:  2017-01-16       Impact factor: 2.570

5.  The efficacy of steroids in reducing morbidity and mortality from extreme hyperthermia and heatstroke-A systematic review.

Authors:  Edward Walter; Oliver R Gibson
Journal:  Pharmacol Res Perspect       Date:  2020-08

Review 6.  Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia.

Authors:  Giuseppe Caruso; Margherita Grasso; Annamaria Fidilio; Fabio Tascedda; Filippo Drago; Filippo Caraci
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-12

7.  Neuroleptic malignant syndrome associated with COVID-19 vaccination.

Authors:  Takahiko Nagamine
Journal:  CJEM       Date:  2021-12-17       Impact factor: 2.929

8.  Immune System Abnormalities in Schizophrenia: An Integrative View and Translational Perspectives.

Authors:  Evgeny A Ermakov; Mark M Melamud; Valentina N Buneva; Svetlana A Ivanova
Journal:  Front Psychiatry       Date:  2022-04-25       Impact factor: 5.435

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.